Talphera (TLPH) Change in Accured Expenses (2010 - 2026)
Talphera's (TLPH) quarterly Change in Accured Expenses came in at -$252000.0 in Q1 2026, up 19.49% year-on-year from -$210898.4 in Q1 2025, and down 146.15% quarter-over-quarter from $546000.0 in Q4 2025.
Talphera (TLPH) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Talphera's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$252000.0 for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 19.49% year-over-year to -$252000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 428.18% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 205.11% from the prior year.
- Change in Accured Expenses retreated to -$252000.0 in Q1 2026 per TLPH's latest filing, from $546000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $891000.0 in Q3 2025 and bottomed at -$1.5 million in Q1 2022.
- The 5-year median for Change in Accured Expenses is -$157000.0 (2022), against an average of -$172705.9.
- Across the five-year window, Change in Accured Expenses sank 538.57% in 2023 and surged 991.0% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at -$157000.0 in 2022, then jumped by 500.64% to $629000.0 in 2023, then plunged by 161.84% to -$389000.0 in 2024, then soared by 240.36% to $546000.0 in 2025, then tumbled by 146.15% to -$252000.0 in 2026.
- Per Business Quant, the three latest TLPH Change in Accured Expenses figures stand at -$252000.0 (Q1 2026), $546000.0 (Q4 2025), and $891000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.58 Bn | 86.72 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.33 Bn | 30.39 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.93 Bn | 16.62 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | - |
| 10 | Talphera | 92.51 Mn | 92.51 Mn | - | -252,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -252,000.00 |
| Mar 31, 2026 | -252,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Sep 30, 2025 | 891,000.00 |
| Sep 30, 2025 | 891,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | -313,000.00 |
| Mar 31, 2025 | -313,000.00 |
| Dec 31, 2024 | -389,000.00 |
| Dec 31, 2024 | -389,000.00 |
| Sep 30, 2024 | -100,000.00 |
| Sep 30, 2024 | -100,000.00 |
| Jun 30, 2024 | 401,000.00 |
| Jun 30, 2024 | 401,000.00 |
| Mar 31, 2024 | -1.11 Mn |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | 629,000.00 |
| Dec 31, 2023 | 629,000.00 |